ClinicalTrials.gg
RecruitingNCT06465056Updated Jun 18, 2024

Use of Botulinum Toxin A in Direct Eyebrow Lift Scar

A Phase 2 interventional study of Botulinum toxin type A in Skin Scarring and Eyebrow Ptosis, sponsored by University of Sao Paulo. Recruiting at 2 sites in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by University of Sao Paulo · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jan 2024, registered May 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing botulinum toxin type A in Cicatrix — 1 open to participants now, 2 under way, none of them phase 3. botulinum toxin type A · Cicatrix.

Planned enrollment
5th of 12
40 · median 36
Started
2024
the only one that year
Phase 2
3 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
University of Sao Paulo

Among the 12 studies testing botulinum toxin type A in Cicatrix, this one is the 5th largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 2, and was the 10th registered.

Cicatrix

613 studies on the registry are indexed under Cicatrix; 115 are open to participants now.

Browse Cicatrix studies →

Open to participants now

1 of the 12 studies testing botulinum toxin type A in Cicatrix is open now, in 1 country.

By country, each count listing its studies:

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing botulinum toxin type A in Cicatrix, or all of them as a file.
02

Study summary

Prospective, controlled and randomized study in which participants indicated for surgery to direct eyebrow lift will be randomized into two groups. In addition to surgery, the patients will be treated with botulinum toxin in one eyebrow and saline (placebo) in the other site. The patients participate as treatment and placebo at the same time. Assessments will be carried out through non-invasive exams.

Read the detailed description

A component of eyebrow ptosis, part of the natural aging process, with or without asymmetries, is found in the majority of patients who seek the blepharoplasty procedure.

There are several procedures to address this condition, but none of them is undoubtedly superior to the others. The direct eyebrow lift technique is known for providing good eyebrow suspension, predictable results and relatively low complexity surgery, which can be performed with local anesthesia.

However, the biggest concern for surgeons and patients is the final appearance of the scar, which will be in a visible area of the face. Botulinum toxin A has been used in recent studies precisely to improve the appearance of scars. Previous studies mainly evaluated traumatic lacerations and post-tumor excision reconstructions, obtaining positive results, with an improvement in the appearance of the wounds in patients who used the medication. It is a safe drug, used for several years for other purposes and without serious adverse effects according to these studies.

The objective of this study is to compare the use of botulinum toxin A versus 0.9% saline solution in the healing of direct eyebrow lift surgery.

03

Conditions studied

  • Skin Scarring
  • Eyebrow Ptosis

Browse trials for

Keywords

  • Botulinum Toxin A
  • Direct eyebrow lift
  • Eyebrow scar
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age with indication for direct eyebrow lift surgery.

Exclusion criteria

Exclusion Criteria:

  • Vulnerable groups: children, pregnant women and patients
  • Allergy to botulinum toxin A
  • Patients under 18 years old
  • Women who are breastfeeding
  • Patients with muscular/neuromuscular diseases such as myasthenia gravis and amyotrophic lateral sclerosis
  • Patients who underwent botulinum toxin A injection in the last 6 months prior to surgery
  • Patients with a history of radiotherapy, chemotherapy or hematological disorders
  • Refusal to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Right side treatment

    Patients receive botulinum toxin A in right side eyebrow scar and saline in left side scar.

    Drug: Botulinum toxin type A

  • Active comparator
    Left side treatment

    Patients receive botulinum toxin A in left side eyebrow scar and saline in right side scar.

    Drug: Botulinum toxin type A

Interventions

06

What researchers measure

Primary outcomes

  1. Scar evaluation 1

    Eyebrow direct lift scar evaluation, comparing botulinum toxin A side with saline side, using the following assessment scale: Visual Analogue Scale Score (VAS). The VAS is described as a quick and practical way of evaluating the patient's experience in relation to pain, on a scale of 0 to 100 millimeters, ranging from no pain to the worst pain imaginable.17 Due to the ease and simplicity of its application, it is used in several studies to evaluate various parameters, even if not consistent with their original validation. Here it will be using meaning 0 (no scar) and 100 milimeters (worst scar imaginable).

    Time frame: One month, three months and six months after surgery

  2. Scar evaluation 2

    Eyebrow direct lift scar evaluation, comparing botulinum toxin A side with saline side, using the following assessment scale: Vancouver Scar Scale (VSS). The VSS ranges from 0 (best) to 13 (worst) points, evaluating vascular distribution, thickness, flexibility and pigmentation.

    Time frame: One month, three months and six months after surgery

  3. Scar evaluation 3

    Eyebrow direct lift scar evaluation, comparing botulinum toxin A side with saline side, using the following assessment scale: Stony Brook Scar Evaluation Scales (SBSESs). The SBSES was developed for short-term assessment of repaired burns, and is described as useful for assessment of suture scars. It consists of five indicators: length, elevation or depression, color, suture or staple marks and general appearance. Your score ranges from 0 (worst) to 5 (best)

    Time frame: One month, three months and six months after surgery

  4. Scar evaluation 4

    Eyebrow direct lift scar evaluation, comparing botulinum toxin A side with saline side, using the following assessment scale: Patient and Observer Scar Assessment Scale (POSAS). POSAS was developed in 2004 and is the first scale to consider the perspective of the patient and the evaluator. It is useful in evaluating postoperative and linear scars, ranging from 5 (worst) to 50 (best). It encompasses physical properties of scars such as vascularity, pigmentation, thickness, relief and flexibility, in addition to two patient symptoms, pain and itching.

    Time frame: One month, three months and six months after surgery

07

Study locations

2 of 2 sites recruiting
  • Ophthalmology Dept. University of Sao Paulo General Hospital
    Sao Paulo, 05403010, Brazil
    Recruiting
    • Suzana Matayoshi, MD · Principal investigator
  • University of São Paulo (Clinical Hospital)
    São Paulo, 05403-010, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.

Of 24 phase 2 interventional studies under Cicatrix, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 61. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2024
First posted
Jun 18, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06465056
Collaborators
University of Campinas, Brazil, Faculdade de Medicina do ABC
Responsible party
Suzana Matayoshi (Professor, University of Sao Paulo) — Principal investigator
First posted
Jun 18, 2024
Start date
Jan 1, 2024
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Jun 18, 2024

Study contacts

Renata Lemos
Contact
rdinizlemos@gmail.com
(11) 2661-7217

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion